Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)

20 de noviembre de 2020 actualizado por: Centre Hospitalier Annecy Genevois

Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.

The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.

For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.

The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.

As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Tipo de estudio

De observación

Inscripción (Actual)

320

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Boulogne Billancourt, Francia
        • Hopital Ambroise Pare Ap-Hp
      • Brest, Francia
        • Centre Hospitalier Universitaire Brest
      • Chambéry, Francia
        • Centre Hospitalier Metropole Savoie
      • Créteil, Francia
        • Centre Hospitalier Intercommunal de Créteil
      • Grenoble, Francia
        • Centre Hospitalier Universitaire Grenoble Alpes
      • Le Chesnay, Francia
        • Centre Hospitalier de Versailles André Mignot
      • Lille, Francia
        • Centre Hospitalier Universitaire de Lille
      • Lyon, Francia
        • Hospices Civils de Lyon
      • Lyon, Francia
        • Centre Leon Berard Lyon
      • Mantes-la-Jolie, Francia
        • Centre Hospitalier François Quesnay
      • Metz-Tessy, Francia, 74374
        • Centre Hospitalier Annecy Genevois
      • Paris, Francia
        • Institut Curie
      • Saint-Cloud, Francia
        • Institut Curie Saint Cloud
      • Saint-Étienne, Francia
        • Institut de Cancérologie Lucien Neuwirth
      • Suresnes, Francia
        • Hôpital Foch

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

The study will include all eligible patients who started paclitaxel-bevacizumab between January 1, 2010 and May 1, 2018. The number of patients is estimated to be approximately 200.

Descripción

Inclusion Criteria:

  • At least 18 years old;
  • Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
  • Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
  • Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
  • Alive patients not opposed to the use of their data

Exclusion Criteria:

  • Patient under guardianship or curatorship at the date of the study ;
  • Patients alive at the time of the study who are opposed to the use of their data
  • Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-free survival
Periodo de tiempo: Up to 12 months
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
Up to 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Drugs administration dosage description
Periodo de tiempo: Up to 12 months
Description of the different monthly drug administration regimens
Up to 12 months
Objective response rate and control rate
Periodo de tiempo: Up to 12 months
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
Up to 12 months
Overall survival Rate
Periodo de tiempo: Up to 12 months
Overall survival, assessed on the whole population
Up to 12 months
Objective Response Rate
Periodo de tiempo: Up to 12 months

Objective Response Rate in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Progression-Free Survival Rate
Periodo de tiempo: Up to 12 months

Progression-Free Survival in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Disease Control Rate
Periodo de tiempo: Up to 12 months

Disease Control in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Overall Survival Rate
Periodo de tiempo: Up to 12 months

Overall Survival in the following subgroups:

  • Patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Frequency of safety events
Periodo de tiempo: Up to 12 months
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
Up to 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Chantal Decroisette, CH Annecy Genevois

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de octubre de 2019

Finalización primaria (Actual)

5 de junio de 2020

Finalización del estudio (Actual)

5 de junio de 2020

Fechas de registro del estudio

Enviado por primera vez

9 de noviembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

20 de noviembre de 2020

Publicado por primera vez (Actual)

23 de noviembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de noviembre de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

20 de noviembre de 2020

Última verificación

1 de noviembre de 2020

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir